Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: A meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 5, 2014, Pages 1825-1833

  Carmichael, John D ^a   Bonert, Vivien S ^a   Nuño, Miriam ^a   Ly, Diana ^a   Melmed, Shlomo ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE CONTROL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; META ANALYSIS; METHODOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT DURATION;

ACROMEGALY; CLINICAL TRIALS AS TOPIC; HUMANS; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 84899955778     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-3757     Document Type: Article

References (31)

1. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119:3189-3202.
2. Ribeiro-Oliveira A, Barkan A. The changing face of acromegaly-advances in diagnosis and treatment. Nat Rev Endocrinol. 2012;8: 605-611.
3. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31:301-342.
4. Giustina A, Chanson P, Bronstein MD, et al.A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-3148.
5. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical'cure.'Eur J Endocrinol. 2005;152:379-387.
6. Jane JA, Starke RM, Elzoghby MA, et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern cr iteria, complications, and predictors of outcome. J Clin Endocrinol Metab. 2011;96:2732-2740.
7. Giustina A, Bronstein MD, Casanueva FF, et al. Current management practices for acromegaly: an international survey. Pituitary. 2011;14:125-133.
8. Melmed S. Medical progress: acromegaly.NEngl J Med. 2006;355: 2558-2573.
9. Weckbecker G Lewis I Albert R Schmid HA Hoyer D Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects Nat Rev Drug Discov. 2003 2 999-1017.
10. Fleseriu M, Delashaw JB, Cook DM. Acromegaly: a review of current medical therapy and new drugs on the horizon. Neurosurg Focus. 2010;29:E15.
11. Lamberts SW, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med. 1985;313:1 576-1580.
12. Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acro-megaly. A randomized, multicenter study. Ann Intern Med. 1992; 117:711-718.
13. Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion o f octreotide (SMS 201-995). Eur J Endocrinol. 1995;132:320-325.
14. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insul in-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13:18-28.
15. Schopohl J, Strasburger CJ, Caird D, et al. Efficacy and acceptability of lanreotide Autogel(R) 120mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes. 2011;119:156-162.
16. Carmichael JD, Bonert VS. Medical therapy: options and uses. Rev Endocr Metab Disord. 2008;9:71-81.
17. Lamberts SW, Oosterom R, Neufeld M, de l Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 1985;60:1161-1165.
18. Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet. 1984;2:782-784.
19. Clemmons DR. Clinical laboratory indices in the treatment of acromegaly. Clin Chim Acta. 2011;412:403-409.
20. Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57:555-559.
21. Bidlingmaier M, Strasburger CJ. Growth hormone assays: current methodologies and their limitations. Pituitary. 2007;10:115-119.
22. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf). 2007;67:65-70.
23. Freda PU, Katzne lson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90:4465-4473.
24. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93:2957-2968.
25. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7:e36411.
26. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000; 85:526-529.
27. Strasburger CJ. Laboratory assessment of GH. Growth Horm IGF Res. 1998;8(suppl A):41-46.
28. Freda PU, Post KD, Powell JS, Wardlaw SL. Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab. 1998 ;83:3808-3816.
29. Milani D, Carmichael JD, Welkowitz J, et al. Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab. 2004;89:2271-2274.
30. Sesmilo G, Gaztambide S, Venegas E, et al. Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary. 2013;16:115-121.
31. Howlett TA Willis D Walker G Wass JA Trainer PJ Acromegaly Register Study Group (UKAR-3). Control of growth hormone and IGF1 in patients with acromegal y in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol (Oxf). 2013 79 689-699.